Asia Pacific Biologics Contract Development Market Size & Outlook
Asia Pacific biologics contract development market, 2018-2030 (US$M)
Related Markets
Asia Pacific biologics contract development market highlights
- The Asia Pacific biologics contract development market generated a revenue of USD 1,583.5 million in 2023.
- The market is expected to grow at a CAGR of 11.1% from 2024 to 2030.
- In terms of segment, mammalian source was the largest revenue generating source in 2023.
- Mammalian Source is the most lucrative source segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,583.5 million |
| Market revenue in 2030 | USD 3,304.7 million |
| Growth rate | 11.1% (CAGR from 2023 to 2030) |
| Largest segment | Mammalian source |
| Fastest growing segment | Mammalian Source |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial Source, Mammalian Source, Other Source |
| Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 19.8% of the global biologics contract development market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,304.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Contract Development Market Scope
Biologics Contract Development Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific biologics contract development market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 53.72% in 2023. Horizon Databook has segmented the Asia Pacific biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
It is to be the fastest growing market, owing to various amendments made by regulatory organizations to change clinical trials evaluation standards according to global requirements and many major players are investing in Asia Pacific.
Countries in Asia Pacific have a dense patient pool and the potential to have advanced medical expertise. The cost of conducting a clinical trial is very low here as compared to the western countries. This drives outsourcing of clinical trials and its related activities in the region.
India has very few regulations on import and export of clinical supplies, which expedites the process. Companies like Novotech and Charles River expanded their services in this region.
Reasons to subscribe to Asia Pacific biologics contract development market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific biologics contract development market databook
-
Our clientele includes a mix of biologics contract development market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biologics contract development market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific biologics contract development market size, by country, 2018-2030 (US$M)
Asia Pacific Biologics Contract Development Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
